Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.09)
# 2,865
Out of 5,182 analysts
112
Total ratings
32.38%
Success rate
-1.23%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $7.36 | +76.63% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $17.83 | +79.47% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $2.50 | +260.00% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $114.36 | -16.93% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $14.09 | +77.43% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $3.42 | +251.39% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $10.52 | +14.07% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $3.08 | +127.27% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.25 | +60.00% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $16.20 | +4.94% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $2.85 | +215.79% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $20.77 | +121.47% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.15 | +595.65% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $38.50 | -37.66% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.08 | +92.31% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.07 | +48.27% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.14 | +308.56% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $3.29 | +386.32% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.69 | +107.10% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.18 | +1,298.21% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $9.12 | +2,732.24% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $7.36
Upside: +76.63%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $17.83
Upside: +79.47%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $2.50
Upside: +260.00%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $114.36
Upside: -16.93%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.09
Upside: +77.43%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $3.42
Upside: +251.39%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $10.52
Upside: +14.07%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.08
Upside: +127.27%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.25
Upside: +60.00%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $16.20
Upside: +4.94%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $2.85
Upside: +215.79%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $20.77
Upside: +121.47%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.15
Upside: +595.65%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $38.50
Upside: -37.66%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.08
Upside: +92.31%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $6.07
Upside: +48.27%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.14
Upside: +308.56%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $3.29
Upside: +386.32%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.69
Upside: +107.10%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.18
Upside: +1,298.21%
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $9.12
Upside: +2,732.24%